The use of doravirme as part of antiretroviral therapy regimens in patients with resistance mutations


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The paper deals with a clinical experience in following up 12 HIV-infected patients with a history of multiple switches to ART regimens and with resistance mutations, who have been switched to an ART DOR/3TC/TDF + DTG regimen in routine clinical practice. The available HIV-1 RNA data show that at one month after switching to a new regimen, 8 of the 12 patients and at 6 month, 8 of the 9 patients achieved an undetectable viral load. Further patient follow-up is needed.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Elena Orlova-Morozova

Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases

Email: orlovamorozova@gmail.com
Cand. Med. Sci., Head, Outpatient Department

Alexander Pronin

Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases

Email: alexanderp909@gmail.com
Cand. Med. Sci., Head

Әдебиет тізімі

  1. Всемирная организация здравоохранения. Глобальная стратегия сектора здравоохранения по ликвидации ВИЧ на 2016-2021. 2016. https://apps.who.int/iris/bitstream/handle/10665/255763/WHO-HIV-2016.05-rus.pdf;jsessionid=09 DCDD724175F1C737E6A1797499F575?sequence=1
  2. Государственная стратегия противодействия распространению ВИЧ- инфекции в Российской Федерации на период до 2020 года и дальнейшую перспективу. Утверждена Распоряжением Правительства РФ от 20.10.2016 № 2203-р. http://government.ru/docs/24983/
  3. Уровень и структура лекарственной устойчивости ВИЧ среди наивных пациентов в Российской Федерации. Анализ Российской базы данных лекарственной устойчивости ВИЧ. www.hivresist.ru
  4. База данных лекарственной устойчивости ВИЧ Стэнфордского университета. https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/#16Larder1995
  5. Cot6 B., Burch J.D., Asante-Appiah E., Bayly Ch., B6dard L, Blouin M. еt al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse ranscriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 2014; 24(3): 917-922. doi: 10.1016/j.bmcl.2013.12.070
  6. Feng M., Sachs N.A., Xu M., Grobler J., Blair W., Hazuda D.J. et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016; 60(4): 22412247. doi: 10.1128/AAC.02650-15
  7. Orkin C., Molina J.-M., Lombaard J., DeJesus E., Rodgers A., Kumar S. et al. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin. Infect. Dis. 2020; 70(7): 1344-1352. doi: 10.1093/cid/ciz424
  8. Johnson M., Kumar P., Molina J.-M., Rizzardini G., Cahn P., Bickel M. et al. for the DRIVE-SHIFT Study Group. Switching to Doravirine/Lamivudine/ Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J. Acquir. Immune Defic. Syndr. 2019; 81(4): 463 -472. doi: 10.1097/ QAI.0000000000002056
  9. Wong A., Goldstein D., Mallolas J., DeJesus E., Johnson M., J.-M. Molina J.-M. et al. Efficacy and Safety of Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/ TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. J. Acquir. Immune Defic. Syndr. 2019; 82(4): e47-e49. doi: 10.1097/QAI.0000000000002153
  10. Soulie C., Santoro M.M., Charpentier C., Storto A., Paraskevis D., Di Carlo D. et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J. Antimicrob. Chemother. 2019; 74(3): 614-617. doi: 10.1093/jac/ dky464

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>